4 completed, 1 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Lymphoma, Malignant: new trials by email Literature Review of Lymphoma, Malignant trials Research Report on Lymphoma, Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| Open-Label, Non Randomized Phase 2 Study With Safety Run-In bimiralisib - Lymphoma, Malignant | Phase 2 | Completed | PIQUR Therapeutics AG | 53 | 2015-05-01 | 2019-09-06 |
| Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma Rituximab - Lymphoma, Malignant | Phase 2 | Completed | Klaus Herfarth, MD | 85 | 2008-03-01 | 2020-01-06 |
| Multi-day Doses in Prevention of Nausea and Emesis Palonosetron, Aprepitant, Dexamethasone - Myeloma, Plasma-Cell, Lymphoma, Malignant | Phase 2 | Completed | University of Kansas Medical Center | 20 | 2007-10-01 | 2017-03-09 |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Reduced intensity conditioning with allogeneic transplant - Myeloma, Plasma-Cell, Lymphoma, Malignant | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 60 | 2000-03-01 | 2012-08-09 |
Lymphoma (5) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Nausea (1) · Primary Myelofibrosis (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms by Histologic Type (5) · Hematologic Diseases (3) · Neoplasms (3) · Blood Protein Disorders (2) · Bone Marrow Diseases (2) · Cardiovascular Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2)
Aprepitant (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Palonosetron (1) · Phosphatidylinositol 3-Kinase (1) · Rituximab (1) · Transplantation, Homologous (1)
Asana BioSciences (1) · Klaus Herfarth, MD (1) · PIQUR Therapeutics AG (1) · University of Kansas Medical Center (1) · University of Michigan Rogel Cancer Center (1)
United States (4) · Argentina (1) · Bosnia and Herzegovina (1) · France (1) · Germany (1) · Israel (1) · Serbia (1) · United Kingdom (1)
Carole Soussain (1) · Danijela Mandic (1) · David Cunningham (1) · Giulino Roth (1) · Graham Collins (1) · Ivan Tijanic (1) · John E. Levine, MS MD (1) · Klaus Herfarth, MD (1) · Nebojsa Andjelkovic (1) · Netanel Horowitz (1) · Niranjan Rao, PhD (1) · Omar Aljitawi, MD (1) · Paul Fields (1) · Rakesh Popat (1) · Sabrina Kurtovic (1)